Céline Hélène Rouquayrol
We have observed 14 EP applications Céline Hélène Rouquayrol has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after October 23, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:
FORMULATIONS COMPRISING 2 -AMINO- 2- [2- (4 - OCTYLPHENYL) ETHYL]PROPANE -1, 3 - DIOL
- IPC classification:
- A61K 31/137, A61K 9/16, A61P 37/06
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ PATENT GRANTED
WASH SOLUTION AND METHOD FOR AFFINITY CHROMATOGRAPHY
- IPC classification:
- C07K 1/22
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ GRANT OF PATENT INTENDED
COMBINATIONS COMPRISING A S1P RECEPTOR MODULATOR
- IPC classification:
- A61K 45/06, A61K 31/4525, A61K 31/343, A61K 31/137, A61K 31/135, A61P 25/24
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ APPLICATION DEEMED TO BE WITHDRAWN
METHOD OF TREATING VISION DISORDERS
- IPC classification:
- C07K 16/22, A61P 27/02
- Applicant:
- Novartis AG
- Agent:
- Multiple attorneys, Novartis Pharma AG
- Status:
- █ APPLICATION DEEMED TO BE WITHDRAWN
Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
- IPC classification:
- A61K 31/137, A61K 9/48, A61K 9/20, A61P 25/00
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ APPLICATION WITHDRAWN
S1P receptor modulators for treating multiple sclerosis
- IPC classification:
- A61K 31/397, A61K 31/137, A61P 37/06
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ APPLICATION DEEMED TO BE WITHDRAWN
Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
- IPC classification:
- A61K 31/137, A61K 9/70, A61K 9/20, A61K 9/00
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ APPLICATION DEEMED TO BE WITHDRAWN
Combinations comprising MGLUR modulators for the treatment of parkinson's disease
- IPC classification:
- A61K 45/06, A61K 31/4725, A61K 31/4709, A61K 31/465, A61K 31/4545, A61K 31/4427, A61K 31/404, A61P 25/16
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ APPLICATION WITHDRAWN
Compound formulations of 2-amino-1,3-propanediol compounds
- IPC classification:
- A61K 47/10, A61K 31/133, A61K 9/00, A61P 37/06, A61P 37/00
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ APPLICATION WITHDRAWN
SYRINGE
- IPC classification:
- A61M 5/315, A61M 5/31, A61M 5/28, A61K 9/00
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ EXAMINATION IN PROGRESS
USE OF A VEGF ANTAGONIST IN TREATING OCULAR VASCULAR PROLIFERATIVE DISEASES
- IPC classification:
- A61K 47/48, A61K 38/17, A61P 27/02
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ EXAMINATION IN PROGRESS
PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES
- IPC classification:
- C07K 16/24, A61K 39/395
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ Request for examination was made
SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES
- IPC classification:
- A61K 39/395, C07K 16/24
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ Request for examination was made
METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
- IPC classification:
- A61K 39/395, C07K 16/24
- Applicant:
- Novartis AG
- Agent:
- Céline Hélène Rouquayrol, Novartis Pharma AG
- Status:
- █ The application has been published